EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Medications for treating alcohol use disorder: A narrative review

Henry R Kranzler iD, Emily E Hartwell iD

Alcohol: Clinical and Experimental Research · 2023-07 · 47 (7) · 1224-1237

DOI: 10.1111/acer.15118 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Alcohol: Clinical and Experimental Research, online erschienen am 08.06.2023. Verfasst von Henry R Kranzler und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 118 Literaturangaben. Gefördert von: CSRD VA, U.S. Department of Veterans Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic heavy alcohol use impacts all major neurotransmitter systems and is associated with multiple medical, psychiatric, and social problems. Available evidence‐based medications to treat alcohol use disorder (AUD) are underutilized in clinical practice. These medications promote abstinence or reduce alcohol consumption, though there are questions regarding their optimal dosage, length of treatment, and utility in combination with one another. Pharmacogenetic approaches, which use a patient's genetic make‐up to inform medication selection, have garnered great interest but have yet to yield results robust enough to incorporate them in routine clinical care. This narrative review summarizes the evidence both for medications approved by the Food and Drug Administration (disulfiram, oral naltrexone, acamprosate, and extended‐release naltrexone) and those commonly used off‐label (e.g., gabapentin, baclofen, and topiramate) for AUD treatment. We discuss these drugs' mechanisms of action, clinical use, pharmacogenetic findings, and treatment recommendations. We conclude that the most consistent evidence supporting the pharmacotherapy of AUD is for the opioid antagonists, naltrexone and nalmefene (which is not approved in the United States), and topiramate. These medications demonstrate consistent small or moderate effects in reducing the frequency of drinking and/or heavy drinking. Lastly, we make suggestions for research needed to refine and expand the current literature on effective pharmacotherapy for AUD.

Schlagwörter

Stichwörter der Autor:innen

alcohol use disordermedicationsmedication‐assisted treatmentpharmacotherapy

Autor:innen und Institutionen

  • Department of Psychiatry, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Veterans Integrated Service Network 4, Mental Illness Research, Education and Clinical Center, Crescenz VAMC, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Henry R Kranzler, Emily E Hartwell

Förderung

  • CSRD VA
  • U.S. Department of Veterans Affairs

Zitieren

APA

Kranzler, H. R., & Hartwell, E. E. (2023). Medications for treating alcohol use disorder: A narrative review. Alcohol: Clinical and Experimental Research, 47(7), 1224-1237. https://doi.org/10.1111/acer.15118

Vancouver

Kranzler HR, Hartwell EE. Medications for treating alcohol use disorder: A narrative review. Alcohol: Clinical and Experimental Research. 2023;47(7):1224-1237. doi:10.1111/acer.15118

BibTeX
@article{Kranzler2023,
  author = {Kranzler, Henry R and Hartwell, Emily E},
  title = {Medications for treating alcohol use disorder: A narrative review},
  journal = {Alcohol: Clinical and Experimental Research},
  year = {2023},
  volume = {47},
  number = {7},
  pages = {1224--1237},
  doi = {10.1111/acer.15118}
}
Kostenlos starten →